The history and progression of treatments for allergic rhinitis

• Published in: Allergy and asthma proceedings Vol. 35 Suppl 1; p. S3
• Main Author: Ostrom, Nancy K
• Format: Journal Article
• Language: English
• Published: United States 01.05.2014
• Subjects: Adrenal Cortex Hormones - administration & dosage; Adrenal Cortex Hormones - history; Adrenal Cortex Hormones - therapeutic use; Anti-Allergic Agents - administration & dosage; Anti-Allergic Agents - history; Anti-Allergic Agents - therapeutic use; Complementary Therapies - history; History, 20th Century; History, 21st Century; Humans; Immunosuppressive Agents - administration & dosage; Immunosuppressive Agents - history; Immunosuppressive Agents - therapeutic use; Immunotherapy - history; Nasal Decongestants - administration & dosage; Nasal Decongestants - history; Nasal Decongestants - therapeutic use; Rhinitis, Allergic - history; Rhinitis, Allergic - therapy
• ISSN: 1539-6304
• DOI: 10.2500/aap.2014.35.3758

This article intends to place new treatments in the context of allergic rhinitis (AR) treatment history. The medical literature was searched for significant advances and changes in AR treatment. Historical data on AR treatment options and management were selected. Reviews of AR management published throughout the 20th century were included to provide context for treatment advances. Modern AR treatment began in the early 20th century with immunotherapy and was soon followed by the emergence of antihistamine therapy in the 1930s. Numerous treatments for AR have been used over the ensuing decades, including decongestants, mast cell stabilizers, and leukotriene receptor antagonists. Topical corticosteroid options were developed the 1950s, and, added to baseline antihistamine therapy, became the foundation of AR treatment. Treatment options were significantly impacted after the 1987 Montreal Protocol, which phased out the use of chlorofluorocarbon propellant aerosols because of environmental concerns. From the mid-1990s until recently, this left only aqueous solution options for intranasal corticosteroids (INSs). The approval of the first hydrofluoroalkane propellant aerosol INSs for AR in 2012 restored a "dry" aerosol treatment option. The first combination intranasal antihistamine/INSs was also approved in 2012, providing a novel treatment option for AR. Treatment of AR has progressed with new therapeutic options now available. This should continue to move forward with agents to alter the allergic mechanism itself and impact the disease burden that has a significant impact on patient outcomes.